TY - JOUR
T1 - In vitro evaluation of a device for intra-pulmonary aerosol generation and delivery
AU - Syedain, Zeeshan H.
AU - Naqwi, Amir A.
AU - Dolovich, Myrna
AU - Somani, Arif
N1 - Publisher Copyright:
Copyright © American Association for Aerosol Research.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - For infants born with respiratory distress syndrome (RDS), liquid bolus delivery of surfactant administered through an endotracheal tube is common practice. While this method is generally effective, complications such as transient hypoxia, hypercapnia, and altered cerebral blood flow may occur. Aerosolized surfactant therapy has been explored as an alternative. Unfortunately, past efforts have led to disappointing results as aerosols were generated outside the lungs with significant pharyngeal deposition and minimal intrapulmonary instillation. A novel aerosol generator (Microjet™) is evaluated herein for intrapulmonary aerosol generation within an endotracheal tube and tested with Curosurf and Infasurf surfactants. Compared with other aerosol delivery devices, this process utilizes low air flow (range 0.01-0.2 L min-1) that is ideal for limiting potential barotrauma to the premature newborn lung. The mass mean diameter (MMD) of the particles for both tested surfactants was less than 4 μm, which is ideal for both uniform and distal lung delivery. As an indicator of phospholipid function, surfactant surface tension was measured before and after aerosol formation-with no significant difference. Moreover, this device has an outside diameter of <1 mm, which permits insertion into an endotracheal tube (of even 2.0 mm). In the premature infant where intravenous access is either technically challenging or difficult, aerosol drug delivery may provide an alternative route in patient resuscitation, stabilization, and care. Other potential applications of this type of device include the delivery of nutrients, antibiotics, and analgesics via the pulmonary route.
AB - For infants born with respiratory distress syndrome (RDS), liquid bolus delivery of surfactant administered through an endotracheal tube is common practice. While this method is generally effective, complications such as transient hypoxia, hypercapnia, and altered cerebral blood flow may occur. Aerosolized surfactant therapy has been explored as an alternative. Unfortunately, past efforts have led to disappointing results as aerosols were generated outside the lungs with significant pharyngeal deposition and minimal intrapulmonary instillation. A novel aerosol generator (Microjet™) is evaluated herein for intrapulmonary aerosol generation within an endotracheal tube and tested with Curosurf and Infasurf surfactants. Compared with other aerosol delivery devices, this process utilizes low air flow (range 0.01-0.2 L min-1) that is ideal for limiting potential barotrauma to the premature newborn lung. The mass mean diameter (MMD) of the particles for both tested surfactants was less than 4 μm, which is ideal for both uniform and distal lung delivery. As an indicator of phospholipid function, surfactant surface tension was measured before and after aerosol formation-with no significant difference. Moreover, this device has an outside diameter of <1 mm, which permits insertion into an endotracheal tube (of even 2.0 mm). In the premature infant where intravenous access is either technically challenging or difficult, aerosol drug delivery may provide an alternative route in patient resuscitation, stabilization, and care. Other potential applications of this type of device include the delivery of nutrients, antibiotics, and analgesics via the pulmonary route.
UR - http://www.scopus.com/inward/record.url?scp=84943381728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84943381728&partnerID=8YFLogxK
U2 - 10.1080/02786826.2015.1067670
DO - 10.1080/02786826.2015.1067670
M3 - Article
C2 - 26884641
AN - SCOPUS:84943381728
SN - 0278-6826
VL - 49
SP - 747
EP - 752
JO - Aerosol Science and Technology
JF - Aerosol Science and Technology
IS - 9
ER -